1.王海燕.肾脏病学.3版.北京：人民卫生出版社，2012.

2.Sparks MA, Crowley SD, Gurley SB, et al. Classical Renin-Angiotensin system in kidney physiology. Compr Physiol, 2014, 4(3)：1201-1228.

3.Boyle SM, Berns JS. Erythropoietin and resistant hypertension in CKD. Semin Nephrol, 2014, 34(5)：540-549.

4.Grasso G, Tomasello F. Erythropoietin for subarachnoid hemorrhage：is there a reason for hope?World Neurosurg, 2012, 77(1)：46-48.

5.Rivkin AM, Chawla S. Epoetin alfa for the treatment of combination therapy-induced hemolytic anemia in patients infected with hepatitis C virus. Pharmacotherapy, 2005 J, 25(6)：862-875.

6.Krishnan M, Nissenson AR. New alternatives in anemia treatment：biosimilars and HIF stabilizers. Nephrol News Issues, 2014, 28(6)：24-28.

7.Henry DH. Experience with epoetin alfa and acquired immunodeficiency syndrome anemia. Semin Oncol, 1998, 25(3 Suppl 7)：64-68.

8.Siragy HM. Rationale for combining a direct renin inhibitor with other renin-angiotensin system blockers. Focus on aliskiren and combinations. Cardiovasc Drugs Ther, 2011, 25(1)：87-97.

9.Miyajima A, Kosaka T, Kikuchi E, et al. Renin-angiotensin system blockade：Its contribution and controversy. Int J Urol, 2015, 22(8)：721-730.

10.Abraham I, MacDonald K. Clinical safety of biosimilar recombinant human erythropoietins. Expert Opin Drug Saf, 2012, 11(5)：819-840.

11.Zitella L. Erythropoietin-stimulating agents：new data yield new insights. Oncology (Williston Park), 2007, 21(11 Suppl Nurse Ed)：36-38.

12.Warrillow SJ. Erythropoietin use in the critically ill：current evidence. Crit Care Resusc, 2008, 10(3)：257-260.